Transcranial Magnetic Stimulator Market Outlook - Forecast Trends, Market Size, Share and Growth Analysis Report (2025-2034)
Description
The global transcranial magnetic stimulator market was valued at USD 1.30 Billion in 2024, driven by the increasing prevalence of neurological diseases like Alzheimer's and Parkinson's (PD) across the globe. The market is anticipated to grow at a CAGR of 9.60% during the forecast period of 2025-2034 to achieve a value of USD 3.25 Billion by 2034.
Transcranial Magnetic Stimulator Market Overview
A transcranial magnetic stimulator (TMS) is a non-invasive device that uses electromagnetic fields to stimulate nerve cells in the brain. It delivers pulsed magnetic fields through a coil placed on the scalp, inducing electrical activity in targeted brain regions. TMS is primarily used for neurological and psychiatric disorders, including depression, anxiety, and chronic pain. It is FDA-approved for treatment-resistant depression and is being explored for conditions like stroke rehabilitation and Parkinson’s disease. TMS is considered safe and well-tolerated, offering a non-pharmaceutical alternative for brain modulation and mental health treatment.
Transcranial Magnetic Stimulator Market Growth Drivers
Advancements in TMS Technology to Drive Market Expansion
The increasing prevalence of mental health disorders and growing regulatory approvals are key drivers of the market. Expanding applications in adolescent and adult mental health treatments further support market growth. For instance, in November 2024, Magstim received FDA clearance for its Horizon Inspire System, a next-generation TMS technology designed to treat major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and anxious depression. This regulatory approval enhances treatment accessibility and supports further technological advancements. As healthcare providers adopt innovative TMS solutions, the market is expected to experience significant growth, with more clinicians, researchers, and mental health professionals integrating these systems into clinical practice.
Surge in Regulatory Approvals to Expand Transcranial Magnetic Stimulator Market Value
Regulatory support and growing clinical validation are accelerating TMS adoption across wider patient demographics. For instance, in March 2024, Neuronetics, Inc. secured FDA approval for its NeuroStar Advanced Therapy as an adjunct treatment for MDD in adolescents aged 15-21. This approval makes NeuroStar the first FDA-cleared TMS treatment for this age group, significantly expanding its market reach. With rising mental health concerns in younger populations and increasing demand for alternative treatments, this development is expected to drive market expansion by enabling broader patient access and supporting continued innovation in TMS therapies.
Transcranial Magnetic Stimulator Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Technological Advancements to Drive Market Growth
The market is witnessing rapid technological advancements, enhancing treatment precision and efficacy. Innovations such as deep TMS (dTMS) and neuronavigation-guided systems improve stimulation depth and targeting accuracy. The integration of artificial intelligence (AI) in treatment planning further optimises therapy outcomes. Additionally, the development of portable and home-based TMS devices is expanding accessibility. These advancements are encouraging broader adoption in psychiatric and neurological applications, fostering market growth. Continuous R&D investments and regulatory approvals for new indications will further propel the market, making TMS a more effective and widely accepted neuromodulation therapy.
Increasing Prevalence of Psychiatric and Neurological Disorders to Influence the Transcranial Magnetic Stimulator Market Size Positively
The growing prevalence of psychiatric and neurological disorders is driving the demand for TMS therapy. A 2021 Lancet Neurology study , supported by the World Health Organization, revealed that over 3 billion people worldwide suffer from neurological conditions. With rising cases of major depressive disorder, obsessive-compulsive disorder, and Parkinson’s disease, non-invasive neuromodulation techniques like TMS are gaining traction. Regulatory approvals for expanded clinical indications are broadening its therapeutic scope. Increasing awareness among healthcare professionals and patients, along with favourable insurance coverage, is accelerating adoption. Moreover, ongoing research into using TMS for cognitive enhancement and Alzheimer’s disease treatment is further strengthening market expansion. As clinical evidence supporting TMS effectiveness continues to grow, the market is expected to witness significant development.
Favourable Regulatory Approvals and Reimbursement Policies to Support Transcranial Magnetic Stimulator Market Value
Regulatory bodies worldwide are increasingly approving transcranial magnetic stimulation (TMS) devices for a wider range of conditions, accelerating market growth. Authorities such as the U.S. FDA and European CE have already cleared TMS for depression and obsessive-compulsive disorder (OCD), with approvals for additional neurological disorders underway. For instance, in August 2024, Neurocare Group received FDA clearance for its intermittent Theta Burst Stimulation (iTBS) protocol, integrated into its Apollo TMS Therapy System and other clinical TMS systems. Additionally, expanding insurance coverage and reimbursement policies are making TMS more accessible, fostering broader adoption and ensuring sustained market expansion in the coming years.
Rising Investments in Research and Development Across Various Domains to Enhance Transcranial Magnetic Stimulator Market Growth
Rising investments in research and development (R&D) are driving innovation in the market. Companies and academic institutions are actively exploring new applications, including stroke rehabilitation, pain management, and addiction treatment. Advanced stimulation protocols and personalised treatment approaches are being developed to improve patient outcomes. Additionally, collaborations between medical device firms and research institutes are accelerating clinical trials and technological breakthroughs. For instance, in June 2024, BrainsWay Ltd. initiated a multicentre clinical trial to evaluate an accelerated deep TMS treatment protocol for major depressive disorder (MDD). The study, involving over 100 patients, will compare a shortened acute treatment phase with the FDA-cleared standard-of-care protocol. If successful, this innovation could enhance treatment accessibility and effectiveness, driving market expansion.
Transcranial Magnetic Stimulator Market Segmentation
Transcranial magnetic stimulation or TMS refers to a non-invasive brain stimulation technique that uses a certain brain area with magnet induction forces. Electromagnetic induction is produced by electricity from a bow, and these pulses pass through the cranium in its specified brain receptor area. There are many different ways for brain stimulation, like electroconvulsive therapy and brain stimulation techniques; however, the most commonly used approach for brain stimulation is the currently transcranial magnetic stimulation technique.
Market Breakup by Type
Repetitive Transcranial Magnetic Stimulation Dominating the Segment by Type
Repetitive Transcranial Magnetic Stimulation (rTMS) is expected to hold the largest market share due to its widespread use in treating depression, anxiety, and neurological disorders. The rising prevalence of mental health conditions, increasing awareness of non-invasive therapies, and technological advancements in TMS devices are driving growth. Additionally, strong clinical evidence supporting rTMS efficacy and expanded regulatory approvals enhance adoption. The segment is poised to grow further with increasing research into new applications, making it a key contributor to market expansion during the forecast period.
Depression to Hold a Substantial Transcranial Magnetic Stimulator Market Value by Application
Depression is anticipated to dominate the market due to the growing global burden of mental health disorders and increasing demand for non-pharmacological treatments. The effectiveness of TMS in treatment-resistant depression has driven adoption, supported by favourable reimbursement policies and clinical endorsements. As per the analysis by Expert Market Research, the anxiety and depression treatment market is expected to grow at a CAGR of 2.6% during the forecast period 2025-2034. Rising mental health awareness, government initiatives, and ongoing research into TMS for psychiatric disorders further strengthen market growth. With depression cases on the rise and healthcare providers prioritising innovative therapies, this segment is set to be the primary driver of market expansion in the coming years.
Hospitals to Lead a Substantial Transcranial Magnetic Stimulator Market Share by End User
Hospitals are expected to lead the market as the primary end users of transcranial magnetic stimulators due to their advanced healthcare infrastructure and high patient influx. The availability of skilled professionals, coupled with increasing investments in neurostimulation technologies, enhances TMS adoption in hospital settings. Moreover, hospitals serve as centres for clinical trials and research, further advancing TMS applications. As awareness grows and hospitals integrate more non-invasive neurological treatments, this segment is poised to drive significant market growth, ensuring accessibility and innovation in neurotherapeutic care.
Transcranial Magnetic Stimulator Market Analysis by Region
North America is expected to dominate the market due to advanced healthcare infrastructure, strong research initiatives, and rising neurological disorder cases. The region benefits from high awareness, favourable reimbursement policies, and increasing government support for mental health treatments. Europe follows closely, driven by technological advancements and expanding clinical applications. The Asia Pacific market is poised for rapid growth, fuelled by increasing healthcare investments and a rising geriatric population.
Leading Players in the Transcranial Magnetic Stimulator Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
BrainsWay Ltd.
BrainsWay Ltd. specialises in deep transcranial magnetic stimulation (dTMS) technology, offering innovative, non-invasive solutions for neurological and psychiatric disorders. Its FDA-cleared systems treat major depressive disorder and obsessive-compulsive disorder, with ongoing research for additional indications. The company’s advanced coil design enhances brain stimulation depth and effectiveness. Strong clinical evidence and continuous R&D investments position BrainsWay as a key player in expanding the global TMS market.
Neuronetics, Inc.
Neuronetics is a pioneer in repetitive transcranial magnetic stimulation (rTMS), widely recognised for its NeuroStar Advanced Therapy system. Focused on treating major depressive disorder, the company leverages technological advancements and strategic collaborations to expand accessibility. Its growing presence in hospitals and psychiatric clinics, coupled with increasing insurance coverage, strengthens its market position. Neuronetics’ commitment to research and innovation ensures continuous improvements in TMS therapy efficacy and adoption.
Magstim
Magstim is a leading provider of transcranial magnetic stimulation devices, offering cutting-edge rTMS solutions for depression and neurological disorders. The company’s high-performance stimulators and accessories support clinical and research applications globally. Magstim’s strong distribution network and focus on training healthcare professionals enhance market penetration. Its continued investment in product development and regulatory approvals strengthens its competitive edge in the expanding neuromodulation market.
MagVenture A/S
MagVenture, a leading provider of transcranial magnetic stimulation (TMS) systems, specialises in innovative neuromodulation solutions for psychiatric and neurological disorders. The company is recognised for its MagPro® magnetic stimulation system, widely used in clinical and research applications. For instance, in May 2024, the company partnered with Magnus Medical to integrate its MagPro® system into the SAINT® neuromodulation therapy. SAINT therapy, an FDA-cleared, rapid-acting treatment, offers MRI-guided TMS for treatment-resistant major depressive disorder (MDD).
Other key players in the market include eNeura Inc., Nexstim Plc, Salience TMS Neuro Solutions, Beckman Coulter, Inc., EB Neuro S.p.A., and Syneika.
Key Questions Answered in the Transcranial Magnetic Stimulator Market
Transcranial Magnetic Stimulator Market Overview
A transcranial magnetic stimulator (TMS) is a non-invasive device that uses electromagnetic fields to stimulate nerve cells in the brain. It delivers pulsed magnetic fields through a coil placed on the scalp, inducing electrical activity in targeted brain regions. TMS is primarily used for neurological and psychiatric disorders, including depression, anxiety, and chronic pain. It is FDA-approved for treatment-resistant depression and is being explored for conditions like stroke rehabilitation and Parkinson’s disease. TMS is considered safe and well-tolerated, offering a non-pharmaceutical alternative for brain modulation and mental health treatment.
Transcranial Magnetic Stimulator Market Growth Drivers
Advancements in TMS Technology to Drive Market Expansion
The increasing prevalence of mental health disorders and growing regulatory approvals are key drivers of the market. Expanding applications in adolescent and adult mental health treatments further support market growth. For instance, in November 2024, Magstim received FDA clearance for its Horizon Inspire System, a next-generation TMS technology designed to treat major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and anxious depression. This regulatory approval enhances treatment accessibility and supports further technological advancements. As healthcare providers adopt innovative TMS solutions, the market is expected to experience significant growth, with more clinicians, researchers, and mental health professionals integrating these systems into clinical practice.
Surge in Regulatory Approvals to Expand Transcranial Magnetic Stimulator Market Value
Regulatory support and growing clinical validation are accelerating TMS adoption across wider patient demographics. For instance, in March 2024, Neuronetics, Inc. secured FDA approval for its NeuroStar Advanced Therapy as an adjunct treatment for MDD in adolescents aged 15-21. This approval makes NeuroStar the first FDA-cleared TMS treatment for this age group, significantly expanding its market reach. With rising mental health concerns in younger populations and increasing demand for alternative treatments, this development is expected to drive market expansion by enabling broader patient access and supporting continued innovation in TMS therapies.
Transcranial Magnetic Stimulator Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Technological Advancements to Drive Market Growth
The market is witnessing rapid technological advancements, enhancing treatment precision and efficacy. Innovations such as deep TMS (dTMS) and neuronavigation-guided systems improve stimulation depth and targeting accuracy. The integration of artificial intelligence (AI) in treatment planning further optimises therapy outcomes. Additionally, the development of portable and home-based TMS devices is expanding accessibility. These advancements are encouraging broader adoption in psychiatric and neurological applications, fostering market growth. Continuous R&D investments and regulatory approvals for new indications will further propel the market, making TMS a more effective and widely accepted neuromodulation therapy.
Increasing Prevalence of Psychiatric and Neurological Disorders to Influence the Transcranial Magnetic Stimulator Market Size Positively
The growing prevalence of psychiatric and neurological disorders is driving the demand for TMS therapy. A 2021 Lancet Neurology study , supported by the World Health Organization, revealed that over 3 billion people worldwide suffer from neurological conditions. With rising cases of major depressive disorder, obsessive-compulsive disorder, and Parkinson’s disease, non-invasive neuromodulation techniques like TMS are gaining traction. Regulatory approvals for expanded clinical indications are broadening its therapeutic scope. Increasing awareness among healthcare professionals and patients, along with favourable insurance coverage, is accelerating adoption. Moreover, ongoing research into using TMS for cognitive enhancement and Alzheimer’s disease treatment is further strengthening market expansion. As clinical evidence supporting TMS effectiveness continues to grow, the market is expected to witness significant development.
Favourable Regulatory Approvals and Reimbursement Policies to Support Transcranial Magnetic Stimulator Market Value
Regulatory bodies worldwide are increasingly approving transcranial magnetic stimulation (TMS) devices for a wider range of conditions, accelerating market growth. Authorities such as the U.S. FDA and European CE have already cleared TMS for depression and obsessive-compulsive disorder (OCD), with approvals for additional neurological disorders underway. For instance, in August 2024, Neurocare Group received FDA clearance for its intermittent Theta Burst Stimulation (iTBS) protocol, integrated into its Apollo TMS Therapy System and other clinical TMS systems. Additionally, expanding insurance coverage and reimbursement policies are making TMS more accessible, fostering broader adoption and ensuring sustained market expansion in the coming years.
Rising Investments in Research and Development Across Various Domains to Enhance Transcranial Magnetic Stimulator Market Growth
Rising investments in research and development (R&D) are driving innovation in the market. Companies and academic institutions are actively exploring new applications, including stroke rehabilitation, pain management, and addiction treatment. Advanced stimulation protocols and personalised treatment approaches are being developed to improve patient outcomes. Additionally, collaborations between medical device firms and research institutes are accelerating clinical trials and technological breakthroughs. For instance, in June 2024, BrainsWay Ltd. initiated a multicentre clinical trial to evaluate an accelerated deep TMS treatment protocol for major depressive disorder (MDD). The study, involving over 100 patients, will compare a shortened acute treatment phase with the FDA-cleared standard-of-care protocol. If successful, this innovation could enhance treatment accessibility and effectiveness, driving market expansion.
Transcranial Magnetic Stimulator Market Segmentation
Transcranial magnetic stimulation or TMS refers to a non-invasive brain stimulation technique that uses a certain brain area with magnet induction forces. Electromagnetic induction is produced by electricity from a bow, and these pulses pass through the cranium in its specified brain receptor area. There are many different ways for brain stimulation, like electroconvulsive therapy and brain stimulation techniques; however, the most commonly used approach for brain stimulation is the currently transcranial magnetic stimulation technique.
Market Breakup by Type
- Deep Transcranial Magnetic Stimulation
- Repetitive Transcranial Magnetic Stimulation
- Others
- Adults
- Children
- Alzheimer’ Disease
- Depression
- Parkinson’s Disease
- Epilepsy
- Hospitals
- Specialty Clinics
- Research Institutes & Academic Centers
- Home Care Settings
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Repetitive Transcranial Magnetic Stimulation Dominating the Segment by Type
Repetitive Transcranial Magnetic Stimulation (rTMS) is expected to hold the largest market share due to its widespread use in treating depression, anxiety, and neurological disorders. The rising prevalence of mental health conditions, increasing awareness of non-invasive therapies, and technological advancements in TMS devices are driving growth. Additionally, strong clinical evidence supporting rTMS efficacy and expanded regulatory approvals enhance adoption. The segment is poised to grow further with increasing research into new applications, making it a key contributor to market expansion during the forecast period.
Depression to Hold a Substantial Transcranial Magnetic Stimulator Market Value by Application
Depression is anticipated to dominate the market due to the growing global burden of mental health disorders and increasing demand for non-pharmacological treatments. The effectiveness of TMS in treatment-resistant depression has driven adoption, supported by favourable reimbursement policies and clinical endorsements. As per the analysis by Expert Market Research, the anxiety and depression treatment market is expected to grow at a CAGR of 2.6% during the forecast period 2025-2034. Rising mental health awareness, government initiatives, and ongoing research into TMS for psychiatric disorders further strengthen market growth. With depression cases on the rise and healthcare providers prioritising innovative therapies, this segment is set to be the primary driver of market expansion in the coming years.
Hospitals to Lead a Substantial Transcranial Magnetic Stimulator Market Share by End User
Hospitals are expected to lead the market as the primary end users of transcranial magnetic stimulators due to their advanced healthcare infrastructure and high patient influx. The availability of skilled professionals, coupled with increasing investments in neurostimulation technologies, enhances TMS adoption in hospital settings. Moreover, hospitals serve as centres for clinical trials and research, further advancing TMS applications. As awareness grows and hospitals integrate more non-invasive neurological treatments, this segment is poised to drive significant market growth, ensuring accessibility and innovation in neurotherapeutic care.
Transcranial Magnetic Stimulator Market Analysis by Region
North America is expected to dominate the market due to advanced healthcare infrastructure, strong research initiatives, and rising neurological disorder cases. The region benefits from high awareness, favourable reimbursement policies, and increasing government support for mental health treatments. Europe follows closely, driven by technological advancements and expanding clinical applications. The Asia Pacific market is poised for rapid growth, fuelled by increasing healthcare investments and a rising geriatric population.
Leading Players in the Transcranial Magnetic Stimulator Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
BrainsWay Ltd.
BrainsWay Ltd. specialises in deep transcranial magnetic stimulation (dTMS) technology, offering innovative, non-invasive solutions for neurological and psychiatric disorders. Its FDA-cleared systems treat major depressive disorder and obsessive-compulsive disorder, with ongoing research for additional indications. The company’s advanced coil design enhances brain stimulation depth and effectiveness. Strong clinical evidence and continuous R&D investments position BrainsWay as a key player in expanding the global TMS market.
Neuronetics, Inc.
Neuronetics is a pioneer in repetitive transcranial magnetic stimulation (rTMS), widely recognised for its NeuroStar Advanced Therapy system. Focused on treating major depressive disorder, the company leverages technological advancements and strategic collaborations to expand accessibility. Its growing presence in hospitals and psychiatric clinics, coupled with increasing insurance coverage, strengthens its market position. Neuronetics’ commitment to research and innovation ensures continuous improvements in TMS therapy efficacy and adoption.
Magstim
Magstim is a leading provider of transcranial magnetic stimulation devices, offering cutting-edge rTMS solutions for depression and neurological disorders. The company’s high-performance stimulators and accessories support clinical and research applications globally. Magstim’s strong distribution network and focus on training healthcare professionals enhance market penetration. Its continued investment in product development and regulatory approvals strengthens its competitive edge in the expanding neuromodulation market.
MagVenture A/S
MagVenture, a leading provider of transcranial magnetic stimulation (TMS) systems, specialises in innovative neuromodulation solutions for psychiatric and neurological disorders. The company is recognised for its MagPro® magnetic stimulation system, widely used in clinical and research applications. For instance, in May 2024, the company partnered with Magnus Medical to integrate its MagPro® system into the SAINT® neuromodulation therapy. SAINT therapy, an FDA-cleared, rapid-acting treatment, offers MRI-guided TMS for treatment-resistant major depressive disorder (MDD).
Other key players in the market include eNeura Inc., Nexstim Plc, Salience TMS Neuro Solutions, Beckman Coulter, Inc., EB Neuro S.p.A., and Syneika.
Key Questions Answered in the Transcranial Magnetic Stimulator Market
- What was the global transcranial magnetic stimulator market value in 2024?
- What is the global transcranial magnetic stimulator market forecast outlook for 2025-2034?
- What is market segmentation based on type?
- What is the market breakup based on age group?
- What is market segmentation based on application?
- What is market segmentation based on end user?
- What are the major factors aiding the global transcranial magnetic stimulator market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major global transcranial magnetic stimulator market trends?
- Which type will lead the market segment?
- Which application will lead the market segment?
- Which end user will lead the market segment?
- Who are the key players involved in the global transcranial magnetic stimulator market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Transcranial Magnetic Stimulator Market Overview
- 3.1 Global Transcranial Magnetic Stimulator Market Historical Value (2018-2024)
- 3.2 Global Transcranial Magnetic Stimulator Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Transcranial Magnetic Stimulator Market Landscape*
- 5.1 Global Transcranial Magnetic Stimulator: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Transcranial Magnetic Stimulator: Product Landscape
- 5.2.1 Analysis by Type
- 5.2.2 Analysis by Age Group
- 5.2.3 Analysis by Application
- 6 Global Transcranial Magnetic Stimulator Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Transcranial Magnetic Stimulator Market Segmentation (218-2034)
- 7.1 Global Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 7.1.1 Market Overview
- 7.1.2 Deep Transcranial Magnetic Stimulation
- 7.1.3 Repetitive Transcranial Magnetic Stimulation
- 7.1.4 Others
- 7.2 Global Transcranial Magnetic Stimulator Market (2018-2034) by Age Group
- 7.2.1 Market Overview
- 7.2.2 Adults
- 7.2.3 Children
- 7.3 Global Transcranial Magnetic Stimulator Market (2018-2034) by Application
- 7.3.1 Market Overview
- 7.3.2 Alzheimer’s Disease
- 7.3.3 Depression
- 7.3.4 Parkinson’s Disease
- 7.3.5 Epilepsy
- 7.4 Global Transcranial Magnetic Stimulator Market (2018-2034) by End User
- 7.4.1 Market Overview
- 7.4.2 Hospitals
- 7.4.3 Specialty Clinics
- 7.4.4 Research Institutes & Academic Centers
- 7.4.5 Home Care Settings
- 7.4.6 Others
- 7.5 Others Global Transcranial Magnetic Stimulator Market (2018-2034) by Region
- 7.5.1 Market Overview
- 7.5.2 North America
- 7.5.3 Europe
- 7.5.4 Asia Pacific
- 7.5.5 Latin America
- 7.5.6 Middle East and Africa
- 8 North America Transcranial Magnetic Stimulator Market (218-2034)
- 8.1 North America Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 8.1.1 Market Overview
- 8.1.2 Deep Transcranial Magnetic Stimulation
- 8.1.3 Repetitive Transcranial Magnetic Stimulation
- 8.1.4 Others
- 8.2 North America Transcranial Magnetic Stimulator Market (2018-2034) by Age Group
- 8.2.1 Market Overview
- 8.2.2 Adults
- 8.2.3 Children
- 8.3 North America Transcranial Magnetic Stimulator Market (2018-2034) by Application
- 8.3.1 Market Overview
- 8.3.2 Alzheimer’s Disease
- 8.3.3 Depression
- 8.3.4 Parkinson’s Disease
- 8.3.5 Epilepsy
- 8.4 North America Transcranial Magnetic Stimulator Market (2018-2034) by End User
- 8.4.1 Market Overview
- 8.4.2 Hospitals
- 8.4.3 Specialty Clinics
- 8.4.4 Research Institutes & Academic Centers
- 8.4.5 Home Care Settings
- 8.4.6 Others
- 8.5 North America Transcranial Magnetic Stimulator Market (2018-2034) by Country
- 8.5.1 United States of America
- 8.5.1.1 United States of America Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 8.5.2 Canada
- 8.5.2.1 Canada Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 9 Europe Transcranial Magnetic Stimulator Market (218-2034)
- 9.1 Europe Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 9.1.1 Market Overview
- 9.1.2 Deep Transcranial Magnetic Stimulation
- 9.1.3 Repetitive Transcranial Magnetic Stimulation
- 9.1.4 Others
- 9.2 Europe Transcranial Magnetic Stimulator Market (2018-2034) by Age Group
- 9.2.1 Market Overview
- 9.2.2 Adults
- 9.2.3 Children
- 9.3 Europe Transcranial Magnetic Stimulator Market (2018-2034) by Application
- 9.3.1 Market Overview
- 9.3.2 Alzheimer’s Disease
- 9.3.3 Depression
- 9.3.4 Parkinson’s Disease
- 9.3.5 Epilepsy
- 9.4 Europe Transcranial Magnetic Stimulator Market (2018-2034) by End User
- 9.4.1 Market Overview
- 9.4.2 Hospitals
- 9.4.3 Specialty Clinics
- 9.4.4 Research Institutes & Academic Centers
- 9.4.5 Home Care Settings
- 9.4.6 Others
- 9.5 Europe Transcranial Magnetic Stimulator Market (2018-2034) by Country
- 9.5.1 United Kingdom
- 9.5.1.1 United Kingdom Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 9.5.2 Germany
- 9.5.2.1 Germany Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 9.5.3 France
- 9.5.3.1 France Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 9.5.4 Italy
- 9.5.4.1 Italy Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 9.5.5 Others
- 10 Asia Pacific Transcranial Magnetic Stimulator Market (218-2034)
- 10.1 Asia Pacific Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 10.1.1 Market Overview
- 10.1.2 Deep Transcranial Magnetic Stimulation
- 10.1.3 Repetitive Transcranial Magnetic Stimulation
- 10.1.4 Others
- 10.2 Asia Pacific Transcranial Magnetic Stimulator Market (2018-2034) by Age Group
- 10.2.1 Market Overview
- 10.2.2 Adults
- 10.2.3 Children
- 10.3 Asia Pacific Transcranial Magnetic Stimulator Market (2018-2034) by Application
- 10.3.1 Market Overview
- 10.3.2 Alzheimer’s Disease
- 10.3.3 Depression
- 10.3.4 Parkinson’s Disease
- 10.3.5 Epilepsy
- 10.4 Asia Pacific Transcranial Magnetic Stimulator Market (2018-2034) by End User
- 10.4.1 Market Overview
- 10.4.2 Hospitals
- 10.4.3 Specialty Clinics
- 10.4.4 Research Institutes & Academic Centers
- 10.4.5 Home Care Settings
- 10.4.6 Others
- 10.5 Asia Pacific Transcranial Magnetic Stimulator Market (2018-2034) by Country
- 10.5.1 China
- 10.5.1.1 China Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 10.5.2 Japan
- 10.5.2.1 Japan Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 10.5.3 India
- 10.5.3.1 India Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 10.5.4 ASEAN
- 10.5.4.1 ASEAN Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 10.5.5 Australia
- 10.5.5.1 Australia Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 10.5.6 Others
- 11 Latin America Transcranial Magnetic Stimulator Market (218-2034)
- 11.1 Latin America Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 11.1.1 Market Overview
- 11.1.2 Deep Transcranial Magnetic Stimulation
- 11.1.3 Repetitive Transcranial Magnetic Stimulation
- 11.1.4 Others
- 11.2 Latin America Transcranial Magnetic Stimulator Market (2018-2034) by Age Group
- 11.2.1 Market Overview
- 11.2.2 Adults
- 11.2.3 Children
- 11.3 Latin America Transcranial Magnetic Stimulator Market (2018-2034) by Application
- 11.3.1 Market Overview
- 11.3.2 Alzheimer’s Disease
- 11.3.3 Depression
- 11.3.4 Parkinson’s Disease
- 11.3.5 Epilepsy
- 11.4 Latin America Transcranial Magnetic Stimulator Market (2018-2034) by End User
- 11.4.1 Market Overview
- 11.4.2 Hospitals
- 11.4.3 Specialty Clinics
- 11.4.4 Research Institutes & Academic Centers
- 11.4.5 Home Care Settings
- 11.4.6 Others
- 11.5 Latin America Transcranial Magnetic Stimulator Market (2018-2034) by Country
- 11.5.1 Brazil
- 11.5.1.1 Brazil Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 11.5.2 Argentina
- 11.5.2.1 Argentina Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 11.5.3 Mexico
- 11.5.3.1 Mexico Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 11.5.4 Others
- 12 Middle East and Africa Transcranial Magnetic Stimulator Market (218-2034)
- 12.1 Middle East and Africa Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Deep Transcranial Magnetic Stimulation
- 12.1.3 Repetitive Transcranial Magnetic Stimulation
- 12.1.4 Others
- 12.2 Middle East and Africa Transcranial Magnetic Stimulator Market (2018-2034) by Age Group
- 12.2.1 Market Overview
- 12.2.2 Adults
- 12.2.3 Children
- 12.3 Middle East and Africa Transcranial Magnetic Stimulator Market (2018-2034) by Application
- 12.3.1 Market Overview
- 12.3.2 Alzheimer’s Disease
- 12.3.3 Depression
- 12.3.4 Parkinson’s Disease
- 12.3.5 Epilepsy
- 12.4 Middle East and Africa Transcranial Magnetic Stimulator Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals
- 12.4.3 Specialty Clinics
- 12.4.4 Research Institutes & Academic Centers
- 12.4.5 Home Care Settings
- 12.4.6 Others
- 12.5 Middle East and Africa Transcranial Magnetic Stimulator Market (2018-2034) by Country
- 12.5.1 Saudi Arabia
- 12.5.2 Saudi Arabia
- 12.5.2.1 Saudi Arabia Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 12.5.3 United Arab Emirates
- 12.5.3.1 United Arab Emirates Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 12.5.4 Nigeria
- 12.5.4.1 Nigeria Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 12.5.5 South Africa
- 12.5.5.1 South Africa Transcranial Magnetic Stimulator Market (2018-2034) by Type
- 12.5.6 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 14.7 Analysis by Key Players
- 15 Grants Analysis
- 15.1 Analysis by Year
- 15.2 Analysis by Amount Awarded
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Grant Application
- 15.5 Analysis by Funding Institute
- 15.6 Analysis by NIH Departments
- 15.7 Analysis by Recipient Organization
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Type of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Strategic Initiatives
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Type of Partnership and Collaborations
- 17.3 Analysis by Joint Ventures
- 17.4 Analysis by Leading Players
- 17.5 Analysis by Geography
- 18 Supplier Landscape
- 18.1 Market Share Analysis, By Region (Top 5 Companies)
- 18.1.1 Market Share Analysis: Global
- 18.1.2 Market Share Analysis: North America
- 18.1.3 Market Share Analysis: Europe
- 18.1.4 Market Share Analysis: Asia Pacific
- 18.1.5 Market Share Analysis: Others
- 18.2 Neuronetics, Inc.
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Company News and Development
- 18.2.5 Certifications
- 18.3 BrainsWay Ltd.
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Company News and Development
- 18.3.5 Certifications
- 18.4 Magstim
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Company News and Development
- 18.4.5 Certifications
- 18.5 MagVenture A/ S
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Company News and Development
- 18.5.5 Certifications
- 18.6 eNeura Inc.
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Company News and Development
- 18.6.5 Certifications
- 18.7 Nexstim Plc
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Company News and Development
- 18.7.5 Certifications
- 18.8 Salience TMS Neuro Solutions
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Company News and Development
- 18.8.5 Certifications
- 18.9 Beckman Coulter, Inc.
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Company News and Development
- 18.9.5 Certifications
- 18.10 Syneika
- 18.10.1 Financial Analysis
- 18.10.2 Product Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Company News and Development
- 18.10.5 Certifications
- 18.11 EB Neuro S. p.A.
- 18.11.1 Financial Analysis
- 18.11.2 Product Portfolio
- 18.11.3 Demographic Reach and Achievements
- 18.11.4 Company News and Development
- 18.11.5 Certifications
- 19 Global Transcranial Magnetic Stimulator Market – Distribution Model (Additional Insight)
- 19.1 Overview
- 19.2 Potential Distributors
- 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
